List view / Grid view

Proteomics

 

Engineering cells and proteins – creating pharmaceuticals

5 September 2014 | By Marco Casteleijn & Dominique Richardson, University of Helsinki

Pharmaceutical biotechnology is big business; it currently consists of 1/6 of the total volume of the pharmaceutical market and continues to grow steadily. Expression of therapeutic proteins is mainly done in living cells, although ‘cell free protein synthesis’ (CFPS) or ‘in-vitro transcription translation’ (IVTT) is beginning to emerge as an…

Pharmaceutical proteomics: a journey from discovery and characterisation of targets to development of high-throughput assays

15 December 2013 | By Joerg Reinders, Institute of Functional Genomics, University of Regensburg

Proteomics has evolved during the last few years from a time-intensive, cost-intensive and hard-to-reproduce technique in basic research to a versatile and reliable tool in various areas of pharmaceutical research. The exploding progress in mass-spectrometry-compatible protein and peptide-separation methods led to the development of new approaches particularly suited for monitoring…

Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?

13 June 2013 | By Thierry Le Bihan, SynthSys and Institute of Structural and Molecular Biology, University of Edinburgh

In recent years, mass spectrometry (MS) based proteomics has moved from being a qualitative tool (used to mainly identify proteins) to a more reliable analysis tool, allowing relative quantitation as well as absolute quantitation of a large number of proteins. However, the developed quantitative methods are either specific for certain…

The role of proteomics in the development of personalised cancer medicine

18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London

Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…

Send this to a friend